Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 10, 2023 2 Forward-Looking Statements This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the generation of XHANCE prescriptions and net revenues and fac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

OptiNose Inc. (NASDAQ:OPTN) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President, Investor Relatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State of other jur ...

OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Conference Call March 7, 2023 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Joe Scodari - Chairman Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies David Amsellem - Piper Sandler Operator Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 E ...

OptiNose, Inc. (NASDAQ:OPTN) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Peter Miller - CEO Ramy Mahmoud - President and COO Conference Call Participants Glenn Santangelo - Jefferies Isaac Somekh - Piper Sandler Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Brandon Folkes - Cantor Jonathan Neely [Starts Abruptly] Third quarter 2022 performance and our plans for the remainder of the year. I'm joined today by our CEO ...

OptiNose, Inc. (NASDAQ:OPTN) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Operator Good day, and thank you for standing by. Welcome to the OptiNose's Second Quarter 2022 Earnings Call. [Operator Instructions] Please be advised that today's conference is being ...

Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 12, 2022 This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: potential for continued XHANCE prescription and net revenue growth and factors supporting such ...

OptiNose, Inc. (NASDAQ:OPTN) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Keith Goldan - CFO Vic Clavelli - Chief Commercial Officer Ramy Mahmoud - President and COO Conference Call Participants Stacey Ku - Cowen Dave Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose First Quarter 2022 Earnings Conference Call. At this ...